Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity

Small molecule inhibitors of PARP1/2 such as olaparib have been proposed to serve as a synthetic lethal therapy for cancers that harbor BRCA1 or BRCA2 mutations. Indeed, in clinical trials PARP1/2 inhibitors elicit sustained anti-tumor responses in patients with germ-line BRCA gene mutations. In hyp...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res
Main Authors: Bajrami, Ilirjana, Frankum, Jessica R., Konde, Asha, Miller, Rowan E., Rehman, Farah L., Brough, Rachel, Campbell, James, Sims, David, Rafiq, Rumana, Hooper, Sean, Chen, Lina, Kozarewa, Iwanka, Assiotis, Ioannis, Fenwick, Kerry, Natrajan, Rachael, Lord, Christopher J., Ashworth, Alan
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4886090/
https://ncbi.nlm.nih.gov/pubmed/24240700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-2541
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki